NEW YORK, Oct. 10, 2017 /PRNewswire/ -- The global
liquid biopsy market should reach $4.5
billion by 2022 from $1.5
billion in 2017 at a compound annual growth rate (CAGR) of
24.2%, from 2017 to 2022.
Read the full report: https://www.reportlinker.com/p03596607
• The global noncancer market is expected to grow from $1.3 billion in 2017 to $2.6 billion in 2022 at a CAGR of 15.2% for the
period 2017-2022.
• The global cancer market is expected to grow from $229.3 million in 2017 to $1.9 billion in 2022 at a CAGR of 52.4% for the
period 2017-2022.
Chapter 1: Introduction
Study Goals and Objectives
BCC Research's goal for this study is to provide an in-depth update
study of the liquid biopsy diagnostics industry, an emerging
industry with high market potential. The global market is analyzed
by application, biomarker type, analysis platform, analysis purpose
and geography. The market sizes are given for the years 2015, 2016,
2017 (estimated) and 2022 (forecasted).
Market segments that provide exceptional growth opportunities
include cancer therapy guidance and monitoring and organ transplant
surveillance.
The report provides a comprehensive discussion of liquid biopsy
technologies, clinical applications, industry structure, liquid
biopsy funding initiatives, global markets, patent status and
companies. The report is designed to provide an in-depth analysis
of the industry and markets and aid companies in their strategic
planning efforts relating to life science tools and
diagnostics.
Reasons for Doing This Study
Traditional biopsy methods are often invasive, uncomfortable and
carry risks of side effects. Liquid biopsy addresses these issues
because it is noninvasive and carries little, if any, side effect
risks.
In the age of genomics and personalized medicine, it is critical
for clinicians to have diagnostic tools that can be used on a
regular basis to screen, monitor, conduct surveillance, guide
treatment or otherwise give valuable genomic information about a
disease. Liquid biopsy provides this capability and thus is of high
interest to the medical community.
Liquid-biopsy-enabling technologies are coming to the forefront and
provide significant market growth momentum to the industry.
Downstream analysis technologies like next-generation sequencing
and digital polymerase chain reaction (PCR) are progressing in
capabilities, efficiency, and costs. Upstream technologies like
microfluidics, cell-free deoxyribo nucleic acid (DNA) capture and
isolation, cell capture, and DNA amplification are also making
significant progress.
Liquid biopsy is also gaining significant traction with key opinion
leaders, medical societies and insurance payors.
As a result, liquid biopsy is penetrating into attractive clinical
applications, including average-risk noninvasive prenatal testing
and cancer therapy guidance and monitoring.
Based on these trends, liquid biopsy markets are rapidly emerging
and the need for industry and market characterization is great.
The outstanding growth potential for liquid biopsy diagnostics
makes it particularly timely for preparing this updated report.
Scope of Report
The scope of the report includes liquid biopsy technologies,
applications, industry subsegments, biomarker technologies, major
funding initiatives, patents and companies. The market sizes for
liquid biopsy diagnostics are given for the years 2015, 2016, 2017
(estimated) and 2022 (forecasted).
This report reviews liquid biopsy biomarkers and technologies and
provides background on why liquid biopsy is increasingly viewed as
a replacement for, or a companion to, tissue biopsy. It then
discusses several of the significant large-scale research
initiatives that are contributing to liquid biopsy development.
Market driving forces are also discussed.
The structure of several important industry subsectors is reviewed,
as well as major industry acquisitions and strategic alliances from
January 2016 through July 2017. Industry subsectors analyzed include
next- generation sequencing (NGS) instruments, droplet digital PCR,
target enrichment and amplification, single-cell DNA polymerase,
prenatal screening, liquid biopsy, direct to consumer, and clinical
laboratory.
The market for liquid biopsy diagnostics is analyzed in depth. The
market is analyzed by application (cancer, reproductive health,
transplant), biomarker type (nucleic acids, cells, extracellular
vesicles, proteins), analysis platform (microarray, NGS, PCR,
proteomics and other), analysis purpose (screening/early detection,
diagnosis, therapy guidance, monitoring) and geography
(North America, Europe, Asia-Pacific, Rest of World). Market data
cover the years 2015, 2016, 2017 (estimated) and 2022
(forecasted).
More than 165 companies in the liquid biopsy industry are profiled
in this report.
BCC Research provides a summary of the main industry acquisitions
and strategic alliances from January
2016 through July 2017,
including key alliance trends.
Information Sources
BCC Research performed both primary and secondary research for this
report. Primary sources included industry companies and leading
research institutions and secondary sources included company
websites and industry, trade and government publications.
Methodology
Both primary and secondary sources were consulted for this report,
and a study of the industry trends was performed. BCC Research
examined each of the key end–user market segments that will be
commercially important during the forecast period: cancer,
transplant medicine and reproductive health.
Based on this analysis, the current and future applications of
liquid biopsy products are evaluated in each of the major clinical
market segments and historical sales revenues are given for 2015
and 2016, estimated revenues are given for 2017, and forecast
revenues are given for 2022.
Geographic Breakdown
In this report, the geographic regions considered for market
analysis include, and only include:
North America
• U.S.
• Mexico.
• Canada.
Europe
• Austria.
• Belgium.
• Czech Republic.
• Denmark.
• Estonia.
• France.
• Finland.
• Germany.
• Greece.
• Hungary.
• Iceland.
• Italy.
• Ireland.
• Luxembourg.
• Netherlands.
• Norway.
• Poland.
• Portugal.
• Romania.
• Spain.
• Sweden.
• Switzerland.
• Turkey.
• U.K.
Asia-Pacific
• Australia.
• China.
• Hong Kong.
• India.
• Japan.
• Malaysia.
• New Zealand.
• Philippines.
• Singapore.
• South Korea.
• Taiwan.
• Thailand.
Rest of World
• Argentina.
• Brazil.
• Chile.
• Israel.
• Kuwait.
• Russia.
• Saudi Arabia.
• South Africa.
• United Arab Emirates.
Liquid Biopsy Market, by Application
Cancer
Reproductive Health
Transplant Medicine
Liquid Biopsy Market, by Biomarker Type
Nucleic Acids
Cells
Extracellular Vesicles
Proteins
Liquid Biopsy Market, by Analysis Platform
Microarray
NGS
PCR
Proteomics
Other
Liquid Biopsy Market, by Analysis Purpose
Screening/Early Detection
Diagnosis
Therapy Guidance
Monitoring
Chapter 2: Summary and Highlights
Liquid biopsy is rapidly gaining traction as a supplement or
alternative to doing a tissue biopsy for applications in
reproductive health, cancer and transplant medicine. The liquid
biopsy captures and analyzes biomarkers, mostly cell-free DNA,
found in body fluids, most often in blood.
In the noninvasive prenatal testing market, liquid biopsy has
achieved significant penetration in the high-risk pregnancy segment
and is moving into the low-risk sector.
In cancer, liquid biopsy is gaining significant market traction.
Two trends stand ou agnostic labeling strategy for cancer drugs is
driving the use of liquid biopsy companion diagnostics. An example
of the former trend is the agreement in June
2017 by the U.S. Department of Veterans Affairs to provide a
liquid biopsy test, PlasmaSelect 64, to advanced cancer patients
being treated at its facilities.
An example of the latter trend is the expanded approval in
May 2017 by the U.S. Food and Drug
Administration (FDA) of the checkpoint inhibitor drug Keytruda
(Merck, pembrolizumab) for advanced cancer patients with
microsatellite instability or mismatch repair deficiency. This
approval highlighted a new paradigm in cancer care, where the
patient is treated based on specific genomic defects rather than on
the organ of origin. This will boost the market for molecular
diagnostics that can detect these genomic markers and be used to
guide treatment decisions associated with these drugs.
The global liquid biopsy market is estimated to be $1.5 billion in 2017 and is growing at a compound
annual growth rate 24.2% to reach a forecast size of $4.5 billion by the year 2022.
The two main applications for liquid biopsy are cancer and
noncancer (reproductive health and organ transplant
diagnostics).
The global cancer market is estimated to be $229.3 million in 2017 and is growing at a
compound annual growth rate of 52.4% to reach a forecast size of
almost $1.9 billion by 2022.
Key growth sectors in the liquid biopsy cancer market include tests
for lung cancer, pan-cancer tests that can detect cancer
recurrence, and tests that can provide real-time assessment of
disease progression or drug response. Liquid biopsy gives
physicians a key tool for assessing whether a patient is taking the
right drug in light of a wider choice of therapies coming onto the
market.
The global noncancer market is estimated at nearly $1.3 billion in 2017 and is growing at a compound
annual growth rate of 15.2% to reach a forecast size of
$2.6 billion by 2022.
Driving this market has been the success of noninvasive prenatal
testing (NIPT) for high-risk pregnancies.
Test providers are focusing on the low-risk sector as well as on
test differentiation as strategies to maintain growth.
A third high-potential market sector for liquid biopsy is for organ
transplantation diagnostics. In this market, there is a strong need
for noninvasive diagnostics that can detect the early onset of
organ rejection so that immunosuppression can be optimized.
Circulating cell-free DNA is fast emerging as the predominant
biomarker for liquid biopsy for all market segments. This creates a
market opportunity for companies who have or can develop
proprietary technologies for improving the workflow for capturing,
detecting and analyzing this biomarker type.
The liquid biopsy industry is dynamic and gaining substantial
traction in its three main clinical market segments. This report
provides a comprehensive overview and analysis of this industry,
which is undergoing exceptional growth and promises to transform
medical treatment and surveillance strategies.
Read the full report: https://www.reportlinker.com/p03596607
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/liquid-biopsy-research-tools-services-and-diagnostics-global-markets-300534161.html
SOURCE Reportlinker